U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H37NO13.ClH
Molecular Weight 680.096
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SABARUBICIN HYDROCHLORIDE

SMILES

Cl.C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3C[C@@](O)(CC4=C3C(O)=C5C(=O)C6=C(C=CC=C6)C(=O)C5=C4O)C(=O)CO)O[C@H]2C

InChI

InChIKey=BSRQHWFOFMAZRL-BODGVHBXSA-N
InChI=1S/C32H37NO13.ClH/c1-12-26(37)17(33)7-21(43-12)46-31-13(2)44-22(8-18(31)35)45-19-10-32(42,20(36)11-34)9-16-23(19)30(41)25-24(29(16)40)27(38)14-5-3-4-6-15(14)28(25)39;/h3-6,12-13,17-19,21-22,26,31,34-35,37,40-42H,7-11,33H2,1-2H3;1H/t12-,13-,17-,18-,19-,21-,22-,26+,31+,32-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C32H37NO13
Molecular Weight 643.6351
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Sabarubicin (previously known as MEN-10755), a disaccharide analog of doxorubicin that was developed by Menarini Pharmaceuticals for the treatment of solid tumors, including small cell lung cancer and prostate cancer. Sabarubicin exhibits a superior antitumor efficacy, presumably related to the activation of p53-independent apoptosis. The drug participated in phase II clinical trials to study its effectiveness in treating patients who have progressive prostate cancer that has not responded to hormone therapy and in chemotherapy-naive patients with extensive stage small cell lung cancer. On 21 December 2004, the European Commission granted the orphan designation to Menarini for sabarubicin for the treatment of small cell lung cancer.

Approval Year

PubMed

PubMed

TitleDatePubMed
Interaction between double helix DNA fragments and the new antitumor agent sabarubicin, Men10755.
2010-02-15
Sabarubicin (MEN10755)-induced apoptosis is independent from mtDNA in A2780 human ovarian tumor cells.
2008-01-30
Sabarubicin.
2008
Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart.
2000-09

Sample Use Guides

Patients received 80 mg/m2 on day one of a 21 day cycle. Dose escalation to 90 mg/m2 was allowed if patients did not experience >Grade 1 toxicity on the first course.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:02:47 GMT 2025
Edited
by admin
on Mon Mar 31 19:02:47 GMT 2025
Record UNII
2Y0GD160CC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEN-10755
Preferred Name English
SABARUBICIN HYDROCHLORIDE
Common Name English
5,12-NAPHTHACENEDIONE, 7-((4-O-(3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)-2,6-DIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXY-9-(HYDROXYACETYL)-, HYDROCHLORIDE (1:1), (7S,9S)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID80873335
Created by admin on Mon Mar 31 19:02:47 GMT 2025 , Edited by admin on Mon Mar 31 19:02:47 GMT 2025
PRIMARY
CAS
169317-77-5
Created by admin on Mon Mar 31 19:02:47 GMT 2025 , Edited by admin on Mon Mar 31 19:02:47 GMT 2025
PRIMARY
PUBCHEM
151896
Created by admin on Mon Mar 31 19:02:47 GMT 2025 , Edited by admin on Mon Mar 31 19:02:47 GMT 2025
PRIMARY
FDA UNII
2Y0GD160CC
Created by admin on Mon Mar 31 19:02:47 GMT 2025 , Edited by admin on Mon Mar 31 19:02:47 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY